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Effects of ayahuasca on mental 
health and quality of life in naïve 
users: A longitudinal and cross-
sectional study combination
Daniel F. Jiménez-Garrido1, María Gómez-Sousa1, Genís Ona1,2, Rafael G. Dos Santos1,3, 
Jaime E. C. Hallak3,4, Miguel Ángel Alcázar-córcoles  5 & José Carlos Bouso  1*
Ayahuasca is a hallucinogenic decoction used as a traditional medicine in several Amazonian regions. 
The ritualistic use of ayahuasca has spread throughout many countries, making it necessary to study 
its risks and benefits. Two sub-studies were designed for this investigation. In sub-study 1, a psychiatric 
interview and a battery of questionnaires were administered to subjects (n = 40) before their first 
ayahuasca use. Two follow-ups were conducted at 1 and 6 months. In sub-study 2, the same interview 
and battery of questionnaires were administered to long-term ayahuasca users (n = 23) and their scores 
were compared with those of the ayahuasca-naïve group. In the first assessment, nearly half (45%) of 
the naïve users were found to meet the diagnostic criteria for a psychiatric disorder. After the ayahuasca 
use, more than 80% of those subjects showed clinical improvements that persisted at 6 months. The 
questionnaires showed significant reductions in depression and psychopathology. Regarding sub-
study 2, long-term users showed lower depression scores, and higher scores for self-transcendence 
and quality of life, as compared to their peers in sub-study 1. Further controlled and observational 
naturalistic studies assessing the eventual risks and potential benefits of ayahuasca are warranted.
Ayahuasca is a psychoactive beverage that results from the decoction of Banisteriopsis caapi and Psychotria viridis, 
plants rich in β-carbolines (harmine or tetrahydroharmine, among others) and N,N-dimethyltryptamine (DMT), 
respectively. DMT is a partial agonist of serotonin (5-HT) receptors1, but it can interact with other receptors as 
well (for a review see Carbonaro & Gatch2). The hallucinogenic effects are primarily caused by the combination 
of the monoamine-oxidase A (MAO-A) inhibiting properties of β-carbolines and DMT, which results in the oral 
bioavailability of the latter3.
Ayahuasca has been traditionally used in several communities of the Amazonia, but in recent decades its use 
has spread throughout the world4, first to urban areas of Brazil, where syncretic religions such as Santo Daime, 
União do Vegetal and Barquinha were established5, and then to other contexts, including several countries of the 
world where ayahuasca retreat centers have been developed and/or neoshamanic groups exist6,7.
Concurrent with this increased public interest in ayahuasca ceremonies, there has been major interest from 
the academic and biomedical fields regarding its potential health effects8,9. Data from observational studies sug-
gest that ayahuasca and its active ingredient DMT may have anxiolytic properties10,11. Furthermore, it has not 
been associated with increased psychopathology or with impairments in neuropsychological functioning12,13. An 
open-label clinical study found significant therapeutic benefits among patients with treatment-resistant major 
depressive disorder (MDD) after the administration of a single dose of ayahuasca14,15. Additionally, one rand-
omized, placebo-controlled clinical trial was recently published, showing that, compared to placebo, a single 
ayahuasca dose was associated with significant reductions in depressive symptoms in MDD patients16.
The mechanisms through which ayahuasca produces therapeutic effects are not completely understood. First, 
DMT is widely found in plants and mammals, including humans17. It acts as a partial agonist at 5-HT receptors, 
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and several studies have shown that the 5-HT2A receptor site could be the main target1. Additionally, neuroimag-
ing studies (described below) show that the neural effects of ayahuasca, in both healthy and depressive subjects, 
are mediated by brain areas rich in 5-HT2A receptors. As far as β-carbolines concerned, they also show potential 
neuroprotective effects besides their MAO-inhibiting properties18.
Beyond the complex effects the isolated compounds have on different neurotransmitter systems, there are 
neuroimaging studies that can help clarify ayahuasca’s potential mechanisms of action. Single photon emission 
computed tomography (SPECT) studies reported that ayahuasca increases blood perfusion in frontal brain 
regions, the insula, the left nucleus accumbens, the left amygdala, the parahippocampal gyrus, and the left subge-
nual area15,19. This pattern suggests that ayahuasca’s effects are related to introspection and emotional processing. 
Studies using functional magnetic resonance imaging (fMRI) have observed activations in the occipital, tem-
poral, and frontal areas of the brain. Remarkably, even with eyes closed, levels of activation in the occipital area 
were consistent with the visionary experience20. Ayahuasca also activates the frontal cortex and areas involved 
in episodic memory. Furthermore, in one study using MRI, an inverse correlation between cortical thickness in 
the posterior cingulate cortex (PCC) and intensity and duration of previous ayahuasca use was observed13. This 
is highly relevant due to the direct implication of PCC in the default mode network (DMN), and it suggests that 
regular ayahuasca use could potentially lead to structural changes in certain brain areas. Evidence of decreased 
DMN activity after ayahuasca use supports this finding21.
Due to the current crisis in psychopharmacology22 and the lack of effective medications for the treatment 
of psychological or neurological disorders23, alongside the continued exoticization of indigenous cultures, the 
number of people attracted by alternative medical practices such as the ritualistic use of ayahuasca has been 
increasing4. Given this context, the effects of ayahuasca should be assessed especially in those people who have no 
previous experience with the decoction. This would help to avoid the bias present in retrospective observational 
studies for which only long-term users were recruited. Those users could be resistant to some of ayahuasca’s 
adverse effects, allowing them to use it without perceiving any harm, and thus they tend to participate as volun-
teers in the studies. However, by analyzing the experience of first-time users, this bias may be better controlled for 
and more accurate information about the overall effects of ayahuasca on novice users can be obtained.
There are some studies that have focused on the assessment of first-time ayahuasca users. Osório et al.14 and 
Sanches et al.15 reported the effects of a single dose of ayahuasca in patients with recurrent depression in an 
open-label study. Fast-acting antidepressant and anxiolytic effects were reported that persisted after 21 days. 
Palhano-Fontes et al.16 published the first randomized, placebo-controlled trial (RCT) in which ayahuasca was 
assessed for the treatment of severe depression and significantly reduced depressive symptoms. In those clinical 
trials, although patients were naïve ayahuasca users, there were carefully selected according to strict inclusion and 
exclusion criteria. Barbosa et al.24, in a non-controlled study, found significant decreases in psychiatric symptoms 
after initial experiences with ayahuasca among a non-clinical sample. Barbosa et al.25 found similar results in a 
follow-up study of the same sample. No adverse effects were reported, and those who began to use ayahuasca 
regularly showed improvements in role-emotional and social functioning scores according to the Short Form-
36 Health Survey (SF-36). Trichter et al.26 analyzed potential changes in spirituality (measured with the Peak 
Experience Profile, the Spiritual Well-being Scale, and the Mysticism Scale as quantitative measures, and an inter-
view as a qualitative measure) after the first ayahuasca experience of 54 people and found that the experience did 
not result in significant changes.
Due to our fieldwork, we know that there are dozens of groups of ayahuasca users in the Spanish territory 
alone, which is a situation that could be relevant to public health9. While some authors describe the communi-
tarian use of ayahuasca as a healthcare system27, some case reports are being published with information about 
psychotic episodes induced by ayahuasca28,29. When elucidating the potential risks of the ritualistic and commu-
nitarian use of ayahuasca, a RCT approach,, would not fit well with the context and the complex variables involved 
in such ritualistic settings. However, observational studies represent a useful and valuable tool for gathering more 
generalizable data. In this case, we designed two observational sub-studies: In sub-study 1, a longitudinal assess-
ment of first time ayahuasca users was conducted. Since it is difficult to find a control group/treatment/condition 
in order to compare results, we designed a sub-study 2, where the baseline assessment of that same group was 
compared with a group of long-term ayahuasca users. In this way, it is possible to find potential differences that 
may be attributed to the regular use of ayahuasca or, on the contrary, are common conditions that may explain 
personal traits that may lead one to get involved in regular ayahuasca use and other spiritual and/or alternative 
health practices. See Fig. 1 for a schematic diagram of the study.
Results
For sub-study 1, we recruited 28 women (70%) and 12 men aged between 20 and 65 years (X  = 35). The majority 
(95%) of subjects were from Spain. Regarding education, the majority (54%) of the sample graduated from uni-
versity. Most participants were atheists (84%). The majority of the sample (59.2%) wanted to take ayahuasca for 
therapeutic purposes, mentioning emotional or psychological issues. Other motivations included self-exploration 
(29.6%), curiosity (11.1%), to have a psychedelic experience (11.1%), to receive insights regarding professional 
development (7.4%), or to start on a spiritual path (3.7%). Regarding the types of ceremonies that participants 
attended, 40% were neoshamanic (led by westerners who traveled to a South American country to learn the meth-
ods of traditional medicine), 37.5% religious (mainly Santo Daime, but also other religious groups derived from 
classical ayahuasca religions), and 22.5% psychotherapeutic (a typical Western approach, in which a psychother-
apeutic setting is used, without religious or shamanic content) ceremonies. As is common in longitudinal studies, 
a smaller number of subjects was retained during follow-ups. While 28 subjects participated in the 1-month 
follow-up, 15 subjects participated in the 6-months follow-up. At baseline, eighteen subjects (45%; 77.7% women) 
met the criteria for one or more psychiatric disorders (50% with comorbidity). The most prevalent diagnoses were 
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generalized anxiety disorder (GAD; n = 6) and substance abuse/dependence (alcohol = 2; cannabis = 2; loraze-
pam = 1). See Table 1.
At the one-month follow-up, the 18 subjects (77.7% women) who met diagnostic criteria were interviewed 
again. Eleven of them (61%) no longer met the criteria for any psychiatric disorder (0% of comorbidity). Four of 
these subjects (22.2%) presented fewer psychiatric diagnoses than at baseline. One subject (5.5%) met the criteria 
for a different psychiatric diagnosis than at baseline. Finally, one subject (5.5%) who did not meet the criteria for 
any psychiatric disorder at baseline did so during the follow-up, meeting the criteria for GAD. Thus, 7 subjects 
met the criteria for psychiatric diagnosis at this time-point. One subject had taken ayahuasca once more since the 
first assessment.
At 6-months follow-up, 15 subjects (60% women) continued their participation in the study. Five subjects took 
ayahuasca again since the 1-month follow-up. Only 8 subjects from the initial 18 who met the criteria for a psy-
chiatric disorder were interviewed. Among those 18 subjects, only 2 still met the criteria for psychiatric diagnosis. 
According to the available information, the subjects who met diagnostic criteria at baseline but did not at the 
1-month follow-up continued to not present diagnostic criteria for any psychiatric disorder. The participant who 
did not meet the diagnostic criteria for a psychiatric disorder at baseline but met the criteria for GAD at 1-month 
follow-up still met the diagnostic criteria for GAD at 6-months follow-up. No other subjects met the criteria for a 
psychiatric disorder, as only 3 subjects met the criteria at the 6-months follow-up.
Regarding the data from the administered questionnaires, at one-month follow-up, lower scores were found 
for two scales of the Symptom Check-List-90-Revised (SCL-90-R): anxiety (d = 0.54), and hostility (d = 0.62). At 
6-months follow-up, lower scores were obtained for the Hamilton Depression Rating Scale (HAM-D) (d = 0.72) 
and in the role-emotional scale (d = 0.74) from the SF-36 questionnaire. See Table 2.
Regarding the subgroup analysis of data from the sample that met criteria for diagnosing psychiatric disor-
ders, all of the CIs overlapped between assessments. However, a tendency was observed in scores obtained by 
most of the questionnaires, as they decreased significantly (data not shown).
Regarding the analysis of potential differences between subjects who dropped out of the study and those 
who remained, there were no significant differences in any variables, neither at one-month nor at the 6-months 
follow-up. However, some tendencies with notable effect sizes were registered. At one-month follow-up, sub-
jects who dropped out of the study tended to obtain lower scores in CAPE-depression symptoms frequency 
[t(35.2) = 2.6, p = 0.01; d = 0.75] and the depression dimension of SCL-90-R [t(37.3) = 2.3, p = 0.02; d = 0.69].
Sub-study 2 was conducted in order to determine if any differences in assessed variables were due to ayahuasca 
use or previous conditions. In this sub-study, the baseline data of the sample for sub-study 1 were compared with 
long-term ayahuasca users’ results for the same variables. We recruited 10 women (43%) and 13 men aged 
between 32 and 64 years (X  = 45). The majority (78.3%) of the subjects were from Spain. Regarding education, 
the majority (32%) of the sample graduated from university. In terms of religious beliefs, most participants were 
atheists (34.8%). The mean number of ayahuasca ceremonies that participants attended was 70 (ranging from 50 
to 100 ceremonies). Only two participants (9%) met the criteria for a psychiatric disorder. One subject met the 
criteria for suicide risk (for attempted suicide), GAD, and obsessive-compulsive disorder (OCD); the other sub-
ject met the criteria for suicide risk (for past attempted suicide) and antisocial personality disorder. See Table 1.
Analyzing data collected through the questionnaires, we found statistically significant differences 
between long-term and ayahuasca naïve users in the HAM-D score [t(53.5) = 2.1, p = 0.03; d = 0.49], the 
self-transcendence scale from the Temperament and Character Inventory (TCI-R-67) [t(61) = 4.6, p < 0.001; 
d = 0.51], and the World Health Organization Quality of Life (WHOQOL-Bref) score [t(61) = 4.3, p < 0.001; 
d = 0.51]. See Table 3.
Regarding the subgroup analysis involving only the sub-study 1 participants who met the criteria for a psy-
chiatric disorder, more differences were found between those participants and the sample of long-term aya-
huasca users. Differences were found in HAM-D score [t(39) = 2.6, p = 0.03; d = 0.77], CAPE-total distress 
score [t(39) = 2.2, p = 0.03; d = 0.68], CAPE-depression symptoms frequency [t(39) = 2.8, p = 0.007; d = 0.87], 
CAPE-depression symptoms distress [t(39) = 2.9, p = 0.006; d = 0.89], CAPE-negative symptoms distress 
[t(39) = 2.4, p = 0.01; d = 0.74], Acceptance and Action Questionnaire (AAQ-II) score [t(39) = 2.3, p = 0.02; 
d = 0.70], ST scale from TCI-R-67 [t(39) = −3.5, p = 0.001; d = 1.10], RE scale from SF-36 [t(39) = −2.5, p = 0.01; 































Figure 1. Schematic diagram of the complete study.
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Discussion
Since ayahuasca use is expanding both internationally and locally in the Spanish context, the aim of this study was 
to observe the effects of ayahuasca on psychological and health variables in naïve ayahuasca users. This will help 
medical practitioners to understand possible adverse effects as well as potential therapeutic uses.
Sub-study 1 Sub-study 2
n % n %
Gender
  Men 12 30% 13 57%
  Women 28 70% 10 43%
Age
  <25 4 10% — —
  25–35 18 45% 2 9%
  36–45 14 35% 14 61%
  46–55 2 5% 4 17%
  56–65 1 2.50% 3 13%
  >65 1 2.50% — —
Education
  Basic education 2 5% 3 14%
  High-school 6 15% 6 27%
  Technical school 3 7.50% 2 9%
  University 21 52.50% 8 32%
  Doctoral degree 8 20% 4 18%
Nationality
  Spain 38 95% 18 78%
  Morocco 1 2.50% — —
  Venezuela 1 2.50% — —
  Italy — — 2 8.7%
  Peru — — 1 4.3%
  Uruguay — — 1 4.3%
  Portugal — — 1 4.3%
Religious beliefs
  Atheists 34 85% 8 34.8%
  Buddhism 2 5% 2 8.7%
  Catholicism 2 5% 1 4.3%
  Shamanism 1 2.5% — —
  Taoism 1 2.5% — —
  Santo Daime 3 13%
MINI interview
  GAD 6 15% 1 4.3%




  Suicide risk 5 12.5% 2 8.7%
  MD 4 10% — —
  Dysthymia 3 7.5% — —
  Past Hypomanic 3 7.5% — —
  episode
  Past manic episode 2 5% — —
  OCD 3 7.5% 1 4.3%
  Antisocial personality 3 7.5% 1 4.3%
  disorder
  Social phobia 1 2.5% — —
  Bulimia 1 2.5% — —
Table 1. Sociodemographic data of the sample. GAD = Generalized Anxiety Disorder; MD = Major 
depression; OCD = Obsessive-Compulsive Disorder.
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We performed two sub-studies. Regarding sub-study 1, 40 ayahuasca-naïve subjects were assessed before 
using ayahuasca for the first time, and they were followed up with at 1 and 6 months after. Following the usual 
pattern of participants in complementary and alternative medicines30, the majority of the sample consisted of 
women with higher education.
The Mini-International Neuropsychiatric Interview (MINI) interview showed that 45% of the sample met 
the diagnostic criteria for a psychiatric disorder. This finding is in line with the main reasons reported by partici-
pants for attending ayahuasca ceremonies, which include the treatment of mental health problems and to achieve 
psychological well-being27,31,32. Remarkably, at the 1-month follow-up, 61% of participants who initially met the 
HAM-D
Baseline (n = 40)
1-month follow-
up (n = 26;)
6-months follow-
up (n = 15)
3.60 [1.77–5.43] 1.75 [0.38–3.12] 0.60 [0–1.35]
CAPE
  Total frequency score 63.3 [59.6–67] 56.2 [49.4–63] 62 [56–68]
  Total distress score 39.2 [31.6–46.9] 35.6 [27.9–43.3] 37.1 [23.2–51]
  Positive symptoms frequency 26.8 [25.1–28.4] 26 [24.7–27.4] 26.9 [23.8–30]
  Positive symptoms distress 10 [7.4–12.6] 8.2 [6.4–10.1] 9.4 [4.7–14.2]
  Depression symptoms frequency 13.5 [12.5–14.4] 12.7 [12–13.5] 12.8 [11.3–14.2]
  Depression symptoms distress 11.5 [9.3–13.5] 11.2 [8.7–13.6] 10.8 [6.8–14.9]
  Negative symptoms frequency 23 [21.4–24.7] 21.5 [19.9–23.1] 22.2 [20.3–24.1]
  Negative symptoms distress 17.7 [14.2–21.2] 16.2 [11.8–20.5] 16.8 [10.7–22.8]
SCL-90-R SOM 0.57 [0.39–0.75] 0.45 [0.34–0.57] 0.91 [0.50–1.32]
  O-C 0.63 [0.43–0.84] 0.44 [0.24–0.64] 0.82 [0.42–1.21]
  I-S 0.60 [0.43–0.78] 0.41 [0.22–0.61] 0.67 [0.25–1.08]
  DEP 0.58 [0.38–0.77] 0.40 [0.21–0.60] 0.70 [0.36–1.04]
  ANX 0.42 [0.28–0.56] 0.24 [0.17–0.31] 0.58 [0.30–0.85]
  HOS 0.52 [0.32–0.73] 0.22 [0.12–0.31] 0.49 [0.23–0.75]
  PHOB 0.07 [0.01–0.13] 0.10 [0.03–0.17] 0.32 [0.1–0.54]
  PAR 0.40 [0.26–0.54] 0.35 [0.21–0.49] 0.65 [0.22–1.07]
  PSY 0.23 [0.12–0.33] 0.13 [0.07–0.19] 0.42 [0.11–0.73]
  GSI 0.48 [0.34–0.62] 0.33 [0.22–0.44] 0.64 [0.34–0.93]
  PSDI 28.3 [22.1–34.5] 23.51 [17.7–29.3] 42.5 [25.1–60]
  PST 1.35 [1.21–1.5] 1.17 [1–1.28] 1.26 [1.07–1.45]
AAQ-II 19.9 [17.3–22.6] 18.2 [15.5–20.8] 18.8 [15.6–22.1]
TCI-R-67 NS 22.4 [20.8–24.1] 21.8 [20.1–23.5] 22.4 [19.2–25.7]
  HA 18.7 [17–20.5] 16.6 [15.2–18.1] 17.7 [16.3–19.1]
  RD 29.2 [26.9–31.4] 30.6 [29–32.2] 30.5 [27.7–33.3]
  PER 25.3 [23.8–26.9] 22.5 [20.3–24.8] 24.2 [22–26.5]
  SELFD 30 [28.8–32.4] 32.3 [30.5–34.2] 31.2 [29.1–33.3]
  COOP 32 [30.6–33.4] 32 [30–34] 31.8 [29.5–34.1]
  ST 20.7 [18.4–23] 21.4 [17.6–25.1] 23.2 [17.8–28.7]
SF-36 PF 97.7 [96–99.5] 98.4 [97.2–99.7] 97.9 [95.8–100]
  RP 87.5 [78.2–96.7] 96.1 [88.2–104] 87.8 [72.3–103.3]
  BP 78 [69.7–86.2] 89.8 [81.7–97.8] 84.6 [70.9–98.3]
  GH 77.5 [71.9–83] 82.5 [77.5–87.5] 72.4 [64.1–80.8]
  VIT 62 [55.6–68.3] 70 [64.5–75.4] 70.7 [62–79.4]
  SF 81.2 [74–88.4] 88.8 [81.2–96.5] 89.1 [79–99.2]
  RE 72.1 [59.3–84.8] 83.3 [70–96.6] 94 [87.1–101]
  MH 69.3 [63.6–75] 74.6 [69.8–79.4] 74.4 [65.6–83.1]
WHOQOL-Bref 17.4 [15.1–19.6] 20.67 [17.9–23.4] 21.4 [18.1–24.7]
Table 2. Means and confidence intervals obtained in sub-study 1. HAM-D = Hamilton Depression Rating 
Scale; SCL-90-R = Symptom Check-List-90-Revised; SOM = Somatizations; O-C = Obsessive-Compulsive; 
I-S = Interpersonal Sensitivity; DEP = Depression; ANX = Anxiety; HOS = Hostility; PHOB = Phobic 
anxiety; PAR = Paranoid ideation; PSY = Psychoticism; GSI = General Severity Index; PSDI = Positive 
Symptoms Distress Index; PST = Positive Symptoms Total; AAQ-II = Acceptance and Action Questionnaire; 
TCI-R-67 = Temperament and Character Inventory Revised; NS = Novelty seeking; HA = Harm voidance; 
RD = Reward dependence; PER = Persistence; SELFD = Self-directedness; COOP = Cooperativeness; ST = Self-
transcendence; SF-36 = The Medical Outcomes Study 36-item Short-Form; PF = Physical function; RP = Role 
physical; BP = Bodily pain; GH = Global health; VIT = Vitality; SF = Social function; RE = Role emotional; 
MH = Mental health; WHOQOL = World Health Organization Quality of Life.
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diagnostic criteria no longer met the criteria for any psychiatric disorder. Additionally, 22.2% of participants 
showed a decrease in the number of psychiatric disorders for which they met the diagnostic criteria, reducing the 
high prevalence of comorbidity at baseline (50%) to 0% at the 1-month follow-up. Overall, 83.2% of participants 
reported a clinical improvement. This improvement lasted until the 6-months follow-up. This finding is surpris-
ing, considering that this clinical improvement reported in the psychiatric interviews was not fully identified by 
the questionnaires used. A reduction in psychiatric diagnoses based on clinical interviews after the initiation of 
ayahuasca use is consistent across studies6,33. These results are also consistent with a recent study published by our 
group where it was found that half of a large sample (n = 380) of long-term ayahuasca users reduced or eliminated 
their prescription drugs after they began to regularly use ayahuasca9.
Only one subject met some criteria for a new psychiatric diagnostic, specifically for GAD, after using aya-
huasca for the first time. That subject met the criteria for this disorder at 6-months follow-up. There are several 
reports regarding adverse effects of ayahuasca, leading some of them to psychiatric diagnoses29. In order to obtain 
more information, the questionnaire scores for this case were checked, and it was noted that the scores on every 
psychopathology scale from the SCL-90-R decreased notably at 1-month follow-up. At 6-months follow-up, half 
of the scales of the SCL-90-R increased again, following the general trend of the whole sample. In the clinical 
interview conducted using the MINI, this subject mentioned that the ayahuasca experience went well, and the 
traumatic termination of a partnership that they were experiencing was a more probable cause of the anxious 
state.
Regarding changes in psychological and psychopathological variables, there were improvements in the 
HAM-D at the 6-months assessment, in anxiety and hostility from the SCL-90-R at the 1-month assessment, 
and in the role-emotional scale from the SF-36 (see Fig. 2). The only variable that showed consistent change 
in the 6-month study period was depression as measured by HAM-D, which improved at every assessment. 
Although differences between baseline and the 1-month follow-up did not reach statistical significance, the scores 
decreased by half. This improvement was more evident at the 6-months follow-up, where differences between 
measures reached statistical significance. This finding is in line with previous research in which ayahuasca showed 
antidepressant effects at 7 and 21 days after its controlled administration in a clinical setting14–16. Our sample was 
not clinical, but 45% of subjects met the criteria for a psychiatric disorder. The same pattern of improvement was 
observed in the role-emotional scale from the SF-36. A similar study with a sample similar to ours also found 
long-term improvements in the role-emotional and social function scales from the SF-36 questionnaire25.
Psychopathology scales of anxiety and hostility from the SCL-90-R only improved at 1-month, but not at 
the 6-months assessment. This tendency was observed for many scales, despite not being statistically signifi-
cant. A general trend of improvement at 1-month follow-up was observed, while this improvement progressively 
decreased up until the 6-months follow-up. This can be clearly seen in Table 3. This pattern suggests that the 
potential therapeutic benefits of ayahuasca are temporary and do not persist in time, excepting for the case of 
depression. Several studies comparing ritual long-term ayahuasca users with non-users or with normative data 
have found better SCL-90-R scores and better scores for other psychopathological and psychological measures in 
users12,13,33,34. This may suggest that the long-term benefits of ayahuasca use depend on maintaining regular use.
The size of the sample decreased at both follow-ups. Therefore, we wanted to understand any potential limi-
tations in that regard, so we conducted comparisons between drop-out subjects and those who remained in the 
study. Despite not obtaining significant results, subjects who scored lower on depression symptoms frequency 
(CAPE), and depression and hostility (SCL-90-R) at baseline tended to remain as study participants at least until 
the first follow-up. There were no significant differences nor notable tendencies between subjects who quit and 
those who remained until the last follow-up regarding any variable. This finding suggests that people with a high 
degree of distress may feel better after ayahuasca use and, subsequently, be more motivated to collaborate with 
researchers.
When only participants who met diagnostic criteria for a psychiatric disorder were analyzed, all the confi-
dence intervals (CI) of variables overlapped between assessments. However, they indicated remarkable decrease 
over time in HAM-D scores, in the psychopathology scores measured by SCL-90-R at the 1-month follow-up, 
decrease in AAQ-II scores at each assessment, and increase of the WHOQOL-Bref score in the same manner. This 
also suggests an improvement in psychopathological status as it was also found using the MINI, but the sample 
may have been too small to observe significant differences using CIs. Despite reporting a clear tendency on the 
questionnaires used, this was not enough so that the CIs did not overlap.
In order to better understand if the eventual differences found between assessments in sub-study 1 were 
attributable to the use of ayahuasca or to extrapharmacological variables, including the passing of time, or if 
there are any pre-conditions that may lead a person to get involved in ayahuasca use, we performed sub-study 2. 
Only the measure of depression, assessed with the HAM-D, showed significant differences between non-users 
and long-term users, where the latter scored better than the former, a finding consistent with the long-term 
antidepressant effects of ayahuasca14–16. In previous studies, the acute administration of ayahuasca reduced the 
functional connectivity (FC) of the default mode network (DMN)21, which could be related to the improvements 
made on a depressed condition35. Moreover, it has been observed that the acute administration of the psyche-
delic tryptamine psilocybin also reduced the FC in the DMN in patients with MDD36 and resulted in a decrease 
in depression scores that lasted for at least 6 months37. Therefore, both the lower scores found at months 1 and 
6 in naïve users and the lower scores for depression found in our long-term users, as compared with the baseline 
scores of subjects from sub-study 1, may reflect an actual mid-term antidepressant effect of ayahuasca. Due to 
the complex effects of ayahuasca, both pharmacological and psychological, employing an integrated approach 
involving different disciplines would be necessary to explain its efficacy. It has been observed, for example, that 
ayahuasca acutely enhances mindfulness-related capacities, such as decentering or acceptance38,39, and psycho-
logical process variables such as personal values could also be involved in therapeutic outcomes34. These capac-
ities seem to be maintained during the after-glow period and also have persistent effects over the long-term40. 
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Long-term effects may also be associated with the integration of the experience into normal life (e.g. by reconcil-
ing unexpressed/unresolved emotional energy), and thus with improvements in psychotherapeutic outcomes41. 
Furthermore, some authors suggest that the psychedelic experience42 or the mystical-type experiences43 that 
psychedelic drugs induce can also explain their therapeutic effects. Finally, as ayahuasca is generally taken in 
HAM-D
Ayahuasca-naïve 
users (n = 40)
Long-term ayahuasca 
users (n = 23)
Ayahuasca-naïve users 
meeting criteria for 
psychiatric disorders (n = 18)
3.60 (5.7) 1.48 (2)* 5.61 (7.2)*
CAPE
  Total frequency score 63.3 (11.5) 63.1 (9.6) 68.6 (13.5)
  Total distress score 39.2 (23.8) 32.5 (17.9) 48 (26.7)*
  Positive symptoms frequency 26.8 (5.2) 28.5 (5.5) 28.7 (5.8)
  Positive symptoms distress 10 (8) 10.5 (7.5) 13 (9)
  Depression symptoms frequency 13.5 (2.9) 12.3 (2.2) 14.9 (3.3)*
  Depression symptoms distress 11.5 (6.5) 8.4 (5.2) 13.9 (6.9)*
  Negative symptoms frequency 23 (5) 22.1 (3.5) 24.9 (6.4)
  Negative symptoms distress 17.7 (11) 13.5 (7.1) 21 (12.4)*
SCL-90-R SOM 0.57 (0.56) 0.72 (0.4) 0.69 (0.6)
  O-C 0.63 (0.64) 0.62 (0.5) 0.85 (0.8)
  I-S 0.60 (0.54) 0.57 (0.5) 0.80 (0.6)
  DEP 0.58 (0.61) 0.56 (0.6) 0.81 (0.7)
  ANX 0.42 (0.43) 0.38 (0.4) 0.56 (0.5)
  HOS 0.52 (0.63) 0.38 (0.6) 0.72 (0.7)
  PHOB 0.07 (0.18) 0.18 (0.2) 0.06 (0.1)
  PAR 0.40 (0.43) 0.60 (0.6) 0.54 (0.4)
  PSY 0.23 (0.33) 0.35 (0.4) 0.30 (0.3)
  GSI 0.48 (0.43) 0.51 (0.4) 0.63 (0.4)
  PSDI 28.3 (19.3) 33 (18.8) 34 (19.4)
  PST 1.35 (0.44) 1.23 (0.3) 1.50 (0.5)
AAQ-II 19.9 (8.3) 18.6 (6.3) 23.9 (8.6)*
TCI-R-67 NS 22.4 (5.1) 22 (3.8) 21.7 (4.6)
  HA 18.7 (5.5) 17.3 (6.3) 20.1 (6.2)
  RD 29.2 (7) 28.8 (6.3) 29.6 (6.8)
  PER 25.3 (4.7) 27.5 (4.4) 26.1 (6)
  SELFD 30 (5.6) 23.1 (5.6) 29.2 (6.3)
  COOP 32 (4.3) 31.8 (4.9) 31.4 (4.4)
  ST 20.7 (7.1) 29.7 (7.9)** 21.2 (7.4)*
SF-36 PF 97.7 (5.4) 96.5 (5.5) 97.7 (6.2)
  RP 87.5 (29) 91.3 (17.8) 89.5 (30.4)
  BP 78 (25.8) 80.4 (21.5) 74.4 (26.1)
  GH 77.5 (17.3) 70.8 (13.8) 76.6 (20.9)
  VIT 62 (19.8) 62.1 (16.2) 56.9 (19.4)
  SF 81.2 (22.4) 87.5 (20) 75 (24.2)
  RE 72.1 (40) 89.8 (29) 61.1 (41.6)*
  MH 69.3 (17.6) 73.7 (19) 62.9 (19.6)
WHOQOL-Bref 17.4 (7) 24.9 (5.5)** 17.2 (8.1)*
Table 3. Means and standard deviations from the sub-study 2. The middle column shows the differences 
observed between ayahuasca-naïve subjects and long-term ayahuasca users. The column on the right shows 
the differences found between long-term users and the ayahuasca-naïve participants who met the criteria 
for diagnosing psychiatric disorders. HAM-D = Hamilton Depression Rating Scale; SCL-90-R = Symptom 
Check-List-90-Revised; SOM = Somatizations; O-C = Obsessive-Compulsive; I-S = Interpersonal Sensitivity; 
DEP = Depression; ANX = Anxiety; HOS = Hostility; PHOB = Phobic anxiety; PAR = Paranoid ideation; 
PSY = Psychoticism; GSI = General Severity Index; PSDI = Positive Symptoms Distress Index; PST = Positive 
Symptoms Total; AAQ-II = Acceptance and Action Questionnaire; TCI-R-67 = Temperament and Character 
Inventory Revised; NS = Novelty seeking; HA = Harm voidance; RD = Reward dependence; PER = Persistence; 
SELFD = Self-directedness; COOP = Cooperativeness; ST = Self-transcendence; SF-36 = The Medical 
Outcomes Study 36-item Short-Form; PF = Physical function; RP = Role physical; BP = Bodily pain; 
GH = Global health; VIT = Vitality; SF = Social function; RE = Role emotional; MH = Mental health; 
WHOQOL = World Health Organization Quality of Life. * = < 0.05; ** = < 0.001.
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ceremonies for which small or large groups of people gather44, its communal use can also be viewed as exerting 
potential benefits, since feeling part of a community can have an important therapeutic impact10.
The other measure where experienced users scored higher than naïve users was self-transcendence (ST). There 
are multiple studies that have shown that psychedelics can induce long-term personality changes45. In sub-study 
1, subjects did not change their scores in ST between assessments, but in sub-study 2 long-term users scored sig-
nificantly higher than non-users in ST, a result that has been consistently found in previous studies as well11,12,24. 
It has been suggested that ayahuasca users’ higher ST scores could be partially explained by their participation 
in religious practices such as Santo Daime. However, in the study by Bouso et al.12 the samples (ayahuasca users 
and non-users) were matched for religion, age, and gender, so the difference in that study could be attributed to 
the ritualistic use of ayahuasca. In the present study, the number of atheists was lower in the group of long-term 
ayahuasca users, but only 13% of participants were Santo Daime members. Taking all these data into account, it 
is reasonable to think that higher scores in ST may be a direct consequence of ayahuasca use. A previous study 
found differences in cortical thickness in several brain areas to exist between long-term users and non-users 
of ayahuasca, suggesting a physical brain modification after regular ayahuasca exposure without any apparent 
neuropsychiatric consequences (there were no differences between groups in their performance on psychiatric 
and neuropsychological tasks)13. In that study, researchers found a correlation between ST and cortical thickness 
in the posterior cingulate cortex13. Psychedelic drugs may therefore offer an interesting tool for investigating the 
stability of personality traits and their brain correlates.
Regarding the differences between naïve ayahuasca users’ and experienced users’ baseline scores for quality 
of life as assessed by the WHOQOL-Bref, they are also consistent between sub-studies. Although in sub-study 
1 there were no significant differences between assessments, there was an actual clinical improvement between 
them (see Table 3). This is consistent with previous research where regular ayahuasca use was associated with a 
better mental health status or with improvement on psychopathology scales, as was also observed in sub-study 1.
When comparing long-term ayahuasca users with the sub-study 1 subsample of psychiatric diagnosis (n = 18), 
the number of variables in which significant differences are found increases. This is reasonable in light of the 
much smaller number of long-term ayahuasca users who met the diagnostic criteria for at least one psychi-
atric disorder (9%). Ayahuasca-naïve users who met the criteria for a psychiatric diagnosis scored poorly for 
depression (HAM-D), positive symptoms frequency (CAPE), depression symptoms distress (CAPE), negative 
symptoms distress, in AAQ-II questionnaire, self-transcendence scale (TCI-R-67), role-emotional (SF-36), and 
Figure 2. Confidence Intervals showing significant differences through different assessments in sub-study 
1. HAM-D = Hamilton Depression Rating Scale; SCL-90-R = Symptom Check-List-90-Revised; SF-36 = The 
Medical Outcomes Study 36-item Short-Form.
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WHOQOL-Bref. Despite not finding statistically significant differences between assessments among the sub-
group of naïve users with psychiatric disorders, remarkable improvements were observed for several scales meas-
uring psychopathology and quality of life. This lends support to previous research that found that ayahuasca users 
gained therapeutic benefits or experienced an enhanced ability to solve personal problems25,33,46.
The main limitation of this study is that there was no control group with which to make comparisons to deter-
mine the impact of the intervention. In order to minimize that limitation, we designed sub-study 2. Coherent 
results were found both between sub-studies and with previously published research. However, further studies 
using larger samples should consider potential differences between the type and setting of the ceremony.
This study assessed naïve users of ayahuasca in order to collect data regarding its overall effects on psychiat-
ric condition and psychological status. Since ayahuasca use has become globally popular as a self-help practice, 
it is important to better understand its potential risks and benefits. General mid-term adverse effects were not 
observed in this study, although some secondary acute reactions were observed in some individual cases (e.g. 
anxiety) and will be reported in a separate paper. Additionally, from a clinical point of view, there was a substan-
tial decrease in psychiatric symptomatology after the first use of ayahuasca, which persisted until the 6-months 
follow-up. The most evident improvements were found with regards to depression. These improvements in 
depression found after performing clinical interviews were also demonstrated by the psychiatric rating scales. 
Better scores for depression were also observed among long-term users when compared with ayahuasca-naïve 
users at baseline. The results obtained in this study help to inform us about the effects of the ritualistic use of 
ayahuasca on mental health. These results suggest that the use of ayahuasca in controlled settings may offer 
therapeutic benefits. Future studies with larger samples are warranted in order to better understand 1) the more 
specific effects of ayahuasca use on public health and 2) the reasons why those initiated in ayahuasca use continue 
to use it or not.
Methods
Sub-study 1. Sample. Several ayahuasca ceremony leaders from different parts of Spain were contacted 
and asked to inform us when ayahuasca-naïve subjects called them to participate in their ayahuasca ceremonies. 
Subjects willing to participate contacted the authors. In this way we recruited 40 ayahuasca-naïve subjects (28 
women) for sub-study 1.
Measures. Sociodemographic information. Age (years), gender (male/female), nationality, maximum educa-
tional level, religion, and motivation for participating in ayahuasca ceremonies were collected from participants.
Mini-International Neuropsychiatric Interview (MINI; Sheehan et al.47; Spanish version: Ferrando et al.48). 
MINI is a short structured diagnostic interview that includes DSM-IV and ICD-10 psychiatric disorders. It is a 
short but accurate tool for use in both clinical trials and epidemiological studies.
Hamilton Depression Rating Scale (HAM-D; Hamilton49; Spanish version: Ramos-Brieva50). HAM-D is a 
questionnaire used to rate the severity of depression through the assessment of various aspects, such as mood, 
suicide ideation, insomnia, anxiety, or somatic symptoms. A score of 0 to 7 is considered to be normal, while a 
score of >7 is indicative of depression.
Community Assessment of Psychic Experience (CAPE; Stefanis et al.51; Spanish version: Fonseca-Pedrero et al.52). 
CAPE was designed specifically to evaluate psychotic-like experiences in epidemiological studies in the general 
population. It contains 42 items and measures psychotic-like experiences using eight sub-scales (Total Frequency 
score; Total Distress score; Positive Symptoms Frequency; Positive Symptoms Distress; Depression Symptoms 
Frequency; Depression Symptoms Distress; Negative Symptoms Frequency; Negative Symptoms Distress) based 
on a dimensional approach.
The Symptom Check-List-90-Revised (SCL-90-R; Derogatis53; Spanish version: González de Rivera et al.54). 
The SCL-90-R is a self-report questionnaire that assesses 9 psychopathological symptomatic dimensions. It 
includes 90 Likert-type items that are scored from 0 to 4: Somatization (SOM), Obsessive-Compulsive (O–C), 
Interpersonal Sensitivity (I–S), Depression (DEP), Anxiety (ANX), Hostility (HOS), Phobic Anxiety (PHOB), 
Paranoid Ideation (PAR), and Psychoticism (PSY). The scale also provides 3 additional psychopathological indi-
ces: General Severity Index (GSI), Positive Symptoms Distress Index (PSDI), and Positive Symptoms Total (PST). 
For all of these scales, higher scores imply worse symptomatology.
Acceptance and Action Questionnaire (AAQ-II; Bond et al.55; Spanish version: Ruiz et al.56). AAQ-II is a 
measure of psychological flexibility that shows good test–retest reliabilities. High scores imply worse psycholog-
ical flexibility.
Temperament and Character Inventory (TCI-R-67; Cloninger57; Spanish version: Pedrero-Pérez et al.58). 
TCI-R-67 is a 67-item self-report questionnaire, in which items are rated between 1 (completely disagree) and 
5 (completely agree), that measures seven domains of personality: Novelty Seeking (NS), Harm Avoidance 
(HA), Reward Dependence (RD), Persistence (PER), Self-directedness (SELFD), Cooperativeness (COOP), and 
Self-transcendence (ST).
The Medical Outcomes Study 36-item Short-Form (SF-36; Ware & Sharebourne59; Spanish version: Alonso 
et al.60). SF-36 has been used in many healthcare settings. It has 8 individual subscales divided across physical 
and psychological domains: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), Global Health (GH), 
Vitality (VIT), Social Function (SF), Role Emotional (RE), and Mental Health (MH).
World Health Organization Quality of Life (WHOQOL-Bref; WHO61; Spanish version: Lucas-Carrasco62). 
WHOQOL-Bref is an abbreviated 26-item version of the WHOQOL-100. It is an assessment tool with 
cross-cultural validity that is used to assess the quality of life.
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Procedure. The interview and questionnaires were administered before ayahuasca-naïve subjects attended 
their first ayahuasca ceremony. One-month and 6-months follow-up were conducted in order to observe poten-
tial changes in variables assessed.
Statistical analysis. An analysis based on confidence intervals (CI; 95%) was used. CIs were calculated 
for each of the variables and assessments. When two CIs of the same variable did not overlap between different 
assessments, we calculated and reported the effect size (Cohen’s d). A subgroup analysis involving only those 
subjects who met psychiatric diagnostic criteria was conducted.
Two Student’s t tests were used to analyze potential differences between those subjects who quit the study at 
both follow-ups and those who did not. Effect size (Cohen’s d) was calculated and reported. Bonferroni correction 
was used for multiple comparisons. P values under 0.001 were considered statistically significant.
IBM SPSS Statistics v.20 was used to analyze the data. An on-line calculator of effect size was used (https://
www.uccs.edu/lbecker/).
Sub-study 2. Sample. The same ayahuasca ceremony facilitators were asked to inform us when 
ayahuasca-experienced subjects (inclusion criterion was established as the participant having taken ayahuasca 
more than 30 times in their lifetime) called them to participate in their ayahuasca ceremonies. Subjects willing 
to participate contacted the authors. A total of 23 ayahuasca-experienced subjects (10 women) were recruited.
Measures. The same measures were used as in sub-study 1.
Procedure. The interview and questionnaires were administered in one single assessment.
Statistical analysis. Student’s t test was used to compare the means obtained for both samples of sub-study 
2. A subgroup analysis was conducted involving only the sub-study 1 subjects who met psychiatric diagnostic 
criteria and comparing them with the sub-study 2 sample.
IBM SPSS Statistics v.20 was used to analyze the data. An on-line calculator of effect size was used (https://
www.uccs.edu/lbecker/).
Ethics. This study (inclusive of sub-studies 1 and 2) was approved by the Research Ethics Committee of the 
Universidad Autónoma de Madrid (Autonomous University of Madrid), Spain. Written informed consent was 
obtained from all volunteers. All experimental procedures were performed in accordance with the relevant guide-
lines and regulations.
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